Latest news

Partnership to Fight Chronic Disease Praises Senate Introduction of the EPIC Act
March 5, 2025 (Washington, D.C.) – The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the introduction of the Ensuring Pathways to Innovative Cures (EPIC) Act in the Senate (S.832). With bicameral legislation now introduced, the EPIC Act has the
Press release
Mar 5,2025
Partnership to Fight Chronic Disease Applauds Reintroduction of the EPIC Act, Highlights Critical Need for Patient-Centered Solutions
February 25, 2025 (Washington, D.C.) – The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to today’s reintroduction of the bipartisan Ensuring Pathways to Innovative Cures (EPIC) Act (H.R. 1492) in Congress. The EPIC ACT will address a flaw in
Press release
Feb 25,2025
Biden Administration’s Latest List of Drugs Selected for Medicare Pricing Exacerbates Access and Innovation Risks to People Living with Cancers & Other Chronic Diseases
  January 17, 2025 (WASHINGTON, D.C.) Today, the Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the Biden Administration’s announcement of 15 new drugs selected for Medicare price negotiations under the Inflation Reduction Act:  
Press release
Jan 17,2025
NEW ANALYSIS SHOWS WEIGHT LOSS SAVES EMPLOYERS AND MEDICARE HEALTH CARE COSTS
Modest weight loss among adults with obesity cuts health care spending by 15%, reduces costs across comorbidities   December 5, 2024 (Washington, D.C.)  Obesity is quickly rising to the top of the list of chronic conditions in the U.S. with more than 40 percent of adults having obesity
Press release
Dec 5,2024
New Poll: Bipartisan Majority Believes Medicare Beneficiaries Should Have Access to FDA-approved Early Alzheimer's Medications the Same Way They Do for All Other Diseases
American voters are willing to pay more to ensure access and want Congress to step in if Medicare continues restricting access to Alzheimer's treatments.   WASHINGTON, DC / ACCESSWIRE / October 10, 2024 / More than four in five voters (82%) favor requiring Medicare and other
Press release
Oct 10,2024
Chronic Disease Patient Groups Call on Congress to Protect Small Molecule Medicine Access and Innovation
September 13, 2024 (Washington, DC) The Partnership to Fight Chronic Disease (PFCD) released the following statement upon delivery of a sign on letter to Congress from more than 30 patient and consumer advocacy groups calling for support of the bipartisan Ensuring Pathways to Innovative Cures (EPIC
Press release
Sep 12,2024
CHRONIC DISEASE COMPLICATES POSTPARTUM HEALTH AMONG BLACK WOMEN
SAN DIEGO, CA – On September 4th, the Partnership to Fight Chronic Disease (PFCD) will host an event in collaboration with California State Assemblymember Dr. Akilah Weber, focusing on the physical and mental health needs of Black women as they navigate the postpartum period. The event will
Press release
Aug 28,2024
PARTNERSHIP TO FIGHT CHRONIC DISEASE RESPONSE TO MEDICARE DRUG PRICE ANNOUNCEMENT
IRA’s “negotiated” prices represent much #MoreThanAList when considering access impacts and lack of savings for millions of chronic disease patients   August 15, 2024 (WASHINGTON, DC) The Partnership to Fight Chronic Disease (PFCD) today released the following statement in
Press release
Aug 15,2024
NEW DATA ILLUSTRATE HUMAN IMPACTS OF FEWER TREATMENTS RESULTING FROM INFLATION REDUCTION ACT’S PRICE CONTROLS
Case studies highlight peril to treatment advances across several disease states   August 14, 2024 (WASHINGTON, DC) The Partnership to Fight Chronic Disease (PFCD) today announced the release of a new data set that highlights critical risks posed to the development and delivery of new
Press release
Aug 14,2024
PFCD APPLAUDS FDA APPROVAL FOR NEW ALZHEIMER’S TREATMENT
Ensuring access and coverage remains a top priority   July 3, 2024 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the U.S. Food and Drug Administration (FDA) traditional approval of KisunlaTM (donanemab), a therapy developed
Press release
Jul 3,2024

Pages